Our previous publications have reported that serum exosomal LDHC overexpression can serve as a multipurpose biomarker for early diagnosis, efficacy assessment, and recurrence monitoring in breast cancer (BC) patients (Cui et al., 2020). Here, LDHC is linked to breast carcinoma.